Published in Hepatitis Weekly, August 18th, 2003
Results from this study support a novel approach to treatment of this disease, whereby hepatitis B virus (HBV)-specific cytotoxic T lymphocytes (CTL) are isolated and expanded for the purpose of fighting disease.
These data were presented in a poster session at the 38th Annual Meeting of the European Association for the Study of the Liver in Geneva, Switzerland. Susanne C. Schneider, PhD, director of Research at CellExSys, presented these data in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.